The FDA approved Genzyme's Mozobil, a drug capable of boosting the number of bone marrow stem cells that can be used for transplant. The treatment is intended for people with non-Hodgkin's lymphoma or multiple myeloma. The clearance covers Mozobil's use with Amgen's Neupogen and other agents designed to trigger the growth and circulation of bone marrow cells in blood.

Full Story:
Bloomberg, Reuters

Related Summaries